REGN Regeneron Pharmaceuticals Inc.

Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards

Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards

Regeneron Science Talent Search Showcases Exceptional Young Leaders with Innovative Ideas in Science, Technology, Engineering and Math (STEM)

TARRYTOWN, N.Y. and WASHINGTON, D.C., Jan. 24, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) and (the Society) today announced the in this year’s , the nation’s oldest and most prestigious science and math competition for high school seniors.

The competition, now in its 83rd year, has consistently identified young innovators who combine their STEM talent with dedication and leadership skills to drive society forward. Program alumni include recipients of the world’s most coveted science and math honors, including 13 Nobel Prizes and 21 MacArthur Foundation Fellowships, as well as the founders of many important science-based companies, including Regeneron.

The 2024 finalists’ research projects showcase their breadth of knowledge, their commitment to addressing issues important to modern society, and their passion for STEM. Multiple students chose to explore research topics such as brain disorders, suicide risk and anxiety. Some students invented accessibility devices, including a robotic arm socket design, glasses for the visually impaired and a column-climbing robot. Other finalists dove into their local environments, studying honeybees and colony collapse disorder as well as prevention of the invasive lantern fly.

“Every year, the Regeneron Science Talent Search helps inspire and engage a new wave of talented young scientists with the potential to improve the world,” said George D. Yancopoulos, M.D., Ph.D., Co-Founder, Board Co-Chair, President and Chief Scientific Officer of Regeneron and a winner in the 1976 STS. “I congratulate these exceptional young finalists as they embark on their scientific journeys. As someone who got my start in this very competition, I know firsthand how the Science Talent Search experience can help jumpstart students’ future academic and career journeys.”

The finalists were chosen based on their projects’ scientific rigor and their potential to become world-changing scientists and leaders. They were selected from 300 scholars, announced earlier this month by Regeneron and the Society for Science. The scholars were chosen from 2,162 qualified entrants, the largest pool of applicants the competition has seen since the 1960s, highlighting the increasing importance of scientific exploration, and outreach and equity programs dedicated to supporting scientific literacy and preparation for competitions. Each student completed an original research project and extensive application process.

"We applaud this dynamic group of Regeneron Science Talent Search finalists on their impressive achievement,” said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News. “As they follow in the footsteps of extraordinary STEM innovators, they are poised to solve the world’s most intractable problems.”

Finalists will participate in a week-long competition from March 6-13, 2024, where they will undergo a rigorous judging process and compete for more than $1.8 million in awards. They will also have an opportunity to interact with leading scientists and share research with the public on March 10, both in person and virtually. The top 10 Regeneron Science Talent Search 2024 winners will be announced during an awards ceremony on March 12, streamed live from Washington D.C.

In total, more than $3 million in awards will be distributed throughout the Regeneron Science Talent Search. Each finalist is awarded at least $25,000, with the top 10 awards ranging from $40,000 to $250,000. Finalists may use their award prize money solely for educational purposes. The top 300 scholars, each of whom receive $2,000, may use their awards as they see fit; each of their schools are also awarded $2,000 to support math and science programs, a critical investment toward their future in STEM, and our country’s future as a hub of innovation and progress.

Regeneron Science Talent Search 2024 Fast Facts

  • The Regeneron Science Talent Search 2024 finalists represent 36 schools across 19 states. They are competing for more than $1.8 million, with a top prize of $250,000.
  • Forty finalists were selected from 300 scholars and 2,162 entrants, the largest pool of applicants since the 1960s, based on the originality and creativity of their scientific research, as well as their achievement and leadership both inside and outside of the classroom.
  • Finalist projects cover disciplines of science including animal sciences, behavioral and social sciences, biochemistry, bioengineering, cellular and molecular biology, chemistry, computational biology and bioinformatics, earth and planetary science, engineering, environmental science, medicine and health genomics, materials science, mathematics, neuroscience, computer science, animal sciences, physics, plant sciences, and space science.

For a list of this year’s finalists, visit

About the Regeneron Science Talent Search

The Regeneron Science Talent Search, a program of Society for Science since 1942, is the nation’s oldest and most prestigious science and math competition for high school seniors. Each year, approximately 2,000 student entrants submit original research in critically important scientific fields of study and are judged by leading experts in their fields. Unique among high school competitions in the U.S. and around the world, the Regeneron Science Talent Search focuses on identifying, inspiring and engaging the nation’s most promising young scientists who are creating the ideas that could solve society’s most urgent challenges.

In 2017, became only the third sponsor of the Science Talent Search to help reward and celebrate the best and brightest young minds and encourage them to pursue careers in STEM as a way to positively impact the world. Through its 10-year, $100 million commitment, Regeneron nearly doubled the overall award distribution to $3.1 million annually, increasing the top award to $250,000 and doubling the awards for the top 300 scholars to $2,000 and their schools to $2,000 for each enrolled scholar to inspire more young people to engage in science.

Learn more at .

About Society for Science

Society for Science is a champion for science, dedicated to promoting the understanding and appreciation of science and the vital role it plays in human advancement. Established in 1921, Society for Science is best known for its award-winning journalism through Science News and Science News Explores, its world-class science research competitions for students, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair and the Thermo Fisher Scientific Junior Innovators Challenge, and its outreach and equity programming that seeks to ensure that all students have an opportunity to pursue a career in STEM. A 501(c)(3) membership organization, Society for Science is committed to inform, educate and inspire. Learn more at and follow us on , , and Snapchat (Society4Science).

About Regeneron

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for over 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases and rare diseases.

Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious disease, to foster a culture of integrity and excellence and to build sustainable communities. Regeneron is proud to be included on the Dow Jones Sustainability World Index and the Civic 50 list of the most “community-minded” companies in the U.S. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro-bono and matching gift programs. Our most significant philanthropic commitments are in the area of science education, including the and .

For additional information about the company, please visit or follow @Regeneron on Twitter.

Media Contacts

Joseph Brown, Regeneron

386-283-1323,    

Gayle Kansagor, Society for Science

703-489-1131,   

 



EN
24/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Regeneron Pharmaceuticals Inc.

 PRESS RELEASE

Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Mye...

Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these responses are expected to deepen over time Across all dose groups, 95% (19 of 20 patients) of all evaluable VGPR+ patients achieved minimal residual disease negative status Data featured in an ASH oral presentation;...

 PRESS RELEASE

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Inv...

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD) TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 million, inclusive of a cash upfront and equity investment from Regeneron; companies to share worldwide development costs and future profits 50:50Collaboration combines Regeneron’s long-standing expertise in genetics, genetic medicines and clinical develop...

 PRESS RELEASE

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the E...

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU) Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatment Dupixent, which inhibits IL-4 and IL-13, two key and central drivers of type 2 inflammation, is now approved for patients across seven chronic, inflamm...

 PRESS RELEASE

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatme...

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing flexibility for more personalized patient care TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has...

 PRESS RELEASE

Libtayo® (cemiplimab) Approved in the European Union as First and Only...

Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free survival in CSCC in the adjuvant setting, reducing the risk of recurrence or death by 68% (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p

ResearchPool Subscriptions

Get the most out of your insights

Get in touch